UCPH-102

• Description :

  UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder[1][2][3][4].

• Product Name Alternative :

  SKQ1

• UNSPSC :

  12352005

• Target :

  EAAT

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ucph-102.html

• Purity :

  99.20

• Solubility :

  DMSO : 8 mg/mL (ultrasonic; warming)

• Smiles :

  N#CC1=C(OC(CC(C2)C3=C4C=CC=CC4=CC=C3)=C(C1C)C2=O)N

• Molecular Formula :

  C21H18N2O2

• Molecular Weight :

  330.38

• References & Citations :

  [1]Huynh TH, et al. Design, synthesis and pharmacological characterization of coumarin-based fluorescent analogs of excitatory amino acid transporter subtype 1 selective inhibitors, UCPH-101 and UCPH-102. Bioorg Med Chem. 2012 Dec 1;20 (23) :6831-9.|[2]Haym I, et al. Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102. ChemMedChem. 2016 Feb 17;11 (4) :403-19.|[3]Stanulović V S, et al. Proliferation and Survival of T-cell Acute Lymphoblastic Leukaemia Depends on mTOR-regulated Glutamine Uptake and EAAT1-dependent Conversion of Glutamine to Aspartate and Nucleotides. bioRxiv. 2020. |[4]Abrahamsen B, et al. Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain. J Neurosci. 2013 Jan 16;33 (3) :1068-87.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  EAAT1

• CAS Number :

  [1229591-56-3]